QM

Quentin McCubbin

Chief Technical Officer

Engrail Therapeutics

Boston, Massachusetts


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Engrail Therapeutics
Industry
pharmaceuticals
Employees
34.0
Seniority
C suite
Total Funding
231000000.0
Latest Funding
Series B

Technologies

Outlook Microsoft Office 365 Google Cloud Hosting Nginx WordPress.org Google Tag Manager Google Font API Mobile Friendly Remote AI Android SharePoint Flutter Python Micro Circle Reviews PEO

Keywords

biotechnology pharmaceuticals drug development drug discovery life sciences pharmaceutical manufacturing neuroscience pharmaceutical clinical-stage precision-targeted transformational therapies neuropsychiatric disorders neurodevelopmental disorders gaba a positive allosteric modulator generalized anxiety disorder gad treatment dopamine d2/d3 receptor antagonist major depressive disorder mdd treatment anhedonia copper transport menkes disease copper ionophore neurodegeneration antidepressant serotonin modulation 5-ht1a 5-ht2a receptor posttraumatic stress disorder ptsd neurotransmission mental health clinical trials phase 2 study drug efficacy treatment adherence neuroscience pipeline drug pharmacokinetics biopharmaceutical clinical operations drug approval neurocircuitry clinical research patient-centric therapies clinical capabilities partnerships biochemical mechanisms disease management functional outcomes chronic conditions psychiatric diseases evidence-based therapies innovative treatments medical hospital & health care health care health wellness & fitness

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans